Recent updates in pulmonary hypertension: New treatment options, inhaled therapy and more

The Healio editors have compiled a list of recent updates in the management and treatment of pulmonary hypertension.

Recent news includes an update from the TRITON study on initial triple oral therapy compared with double therapy in newly diagnosed PAH; new data on inhaled treprostinil and inhaled nitric oxide; selexipag in children; and more. Read these articles, and others, below.

Initial triple therapy vs. double may improve outcomes in newly diagnosed PAH: TRITON

In patients with newly diagnosed PAH, initial triple oral therapy, compared with double therapy, both improved hemodynamics, NT-proBNP and functional capacity, with no difference between strategies at 26 weeks. Read more

Inhaled nitric oxide at higher dose shows benefit in pulmonary hypertension, fibrotic ILD

Pulsed, inhaled nitric oxide at a higher dose was safe and well tolerated, and resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease. Read more

Inhaled treprostinil improves QOL, other exploratory outcomes in patients with PAH

New exploratory endpoint data from the INSPIRE study show improvements after 2 months of treatment with inhaled treprostinil in quality of life, 6-minute walk distance and New York Heart Association functional class. Read more

New research widens continuum of risk associated with PVR in pulmonary hypertension

New data expand the range of pulmonary vascular resistance associated with mortality and heart failure in patients at risk for pulmonary hypertension undergoing right heart catheterization. Read more

Selexipag well tolerated, safe in children with PAH

Use of oral add-on selexipag in children was well tolerated, safe and improved PAH outcomes, according to data published in The Journal of Heart and Lung Transplantation. Read more

PAH outcomes improved in specialty care centers

Patients with PAH treated in a specialty care center had improved mortality and hospitalization, according to a study published in CHEST. Read more

Inhaled treprostinil improves outcomes in ILD-associated pulmonary hypertension

Inhaled treprostinil was well tolerated and significantly improved exercise capacity and other clinical outcomes over 16 weeks in patients with pulmonary hypertension associated with ILD, according to results of the INCREASE study. Read more

Sotatercept decreases pulmonary vascular resistance in PAH: PULSAR

In the phase 2 PULSAR trial, treatment with sotatercept for 24 weeks resulted in greater reduction in pulmonary vascular resistance than placebo in patients with PAH on stable background therapies. Read more

Exercise rehabilitation low among US veterans with pulmonary hypertension

Few patients with primary PAH were treated with exercise rehabilitation in the form of pulmonary or cardiac rehabilitation. Read more